There is strong evidence that GLP-1 medications can: Improve HbA1c and blood glucose control Support appetite regulation Improve cardiovascular risk markers in some populations Support improvements in cholesterol and triglycerides Lower blood pressure (modestly) Reduce risk of major cardiovascular events in higher-risk individuals For many people, these changes occur independently of weight reduction and are linked to improved metabolic functioning
Ordering peptides from unregulated online sources can pose serious quality, legal, and health risks
We found that homozygous knockin of the L973F-IR in mice results in alterations in signaling similar to those observed in vitro, i.e., decreased IRS-1mediated signaling and increased Shc-mediated signaling, and these lead to impaired insulin sensitivity and modest increases in either tibial or whole-animal growth
Thus, NGS ruled out recombination between different genotypes as the cause of these rare discordant results
doi: 10.3389/fnagi.2019.00088 98 DeaconCFJohnsenAHHolstJJ
All treatments are subject to provider review, medical appropriateness, and clinical discretion
